NASDAQ$DERM
Journey Medical Corp · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Journey Medical reported Q1 2026 product revenue of $15.9M with a net loss of $2.2M and diluted loss per share of $0.08.
For the quarter ended March 31, 2026, Journey Medical (DERM) generated product revenue of $15.9 million, up from $13.1 million, and a net loss of $2.2 million versus $4.1 million a year ago. Diluted loss per share improved to $0.08 from $0.18. Gross margin expanded as revenue grew while operating expenses were $17.5 million. The company satisfied a $60M revenue threshold to extend interest-only terms on its credit facility to February 2027.
- Product revenue rose to $15.9M from $13.1M year over year.
- Net loss narrowed to $2.2M; diluted EPS was a loss of $0.08.
- Operating loss improved to $1.5M from $3.3M.
- Credit facility principal payments deferred until February 2027 after revenue covenant met.
- SG&A of $10.1M remained the largest operating cost line.
Headline financials
Revenue & EPS history
Journey Medical · Revenue · Quarterly
$16M
Forward guidance
The 10-Q does not provide formal EPS or revenue guidance. Management discusses commercial execution for dermatology brands and the extended interest-only period on debt after surpassing $60M trailing revenue.
Tailwinds
- Revenue growth and narrower net loss improved per-share results.
- Debt covenant relief delays principal amortization until 2027.
Headwinds
- Company remains loss-making with meaningful SG&A and interest expense.
- No explicit forward financial targets were disclosed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2026
-2.9%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+5.1%
Avg return
30 days after
39%
9 / 23 earnings
Positive
+22.0%
Q1 2025
Best reaction
-26.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -26.8% | -1.1% | — | |
| Q1 2026 | +3.0% | +24.4% | +26.5% | |
| Q3 2025 | -15.3% | -12.4% | -15.5% | |
| Q2 2025 | -15.1% | -18.0% | -16.7% | |
| Q1 2025 | +22.0% | +15.2% | +13.6% | |
| Q4 2024 | -3.6% | -2.8% | +21.7% | |
| Q3 2024 | -8.2% | -7.5% | -9.3% | |
| Q2 2024 | -3.2% | -11.0% | -3.8% | |
| Q1 2024 | +2.8% | -1.7% | +69.2% | |
| Q4 2023 | -14.1% | -3.9% | -9.4% | |
| Q3 2023 | +15.7% | +14.8% | +105.5% | |
| Q2 2023 | +14.0% | +4.7% | +21.5% | |
| Q1 2023 | -10.1% | -23.2% | +44.9% | |
| Q4 2022 | +3.1% | +13.1% | +26.3% | |
| Q3 2022 | -8.7% | -9.2% | -27.2% | |
| Q2 2021 | -4.3% | -7.0% | -30.1% | |
| Q2 2022 | -4.3% | -7.0% | -30.1% | |
| Q1 2022 | -12.3% | +5.1% | +0.8% | |
| Q1 2021 | -12.3% | +5.1% | +0.8% | |
| Q4 2021 | +5.4% | +6.1% | -1.8% | |
| Q3 2020 | +3.4% | -0.1% | -24.3% | |
| Q4 2020 | +3.4% | -0.1% | -24.3% | |
| Q3 2021 | +0.0% | +0.0% | -25.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro